Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
25 janv. 2024 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD),...
Pan-Biome Pharmaceuticals, a startup focused on age-related diseases and increasing human healthspan, reports positive results in a preclinical trial of colitis
25 avr. 2023 10h00 HE
|
Pan-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on age-related diseases and extending...
Global Ulcerative Colitis Market Is Expected to Reach $10.8 Billion by 2030: Says AMR
03 juil. 2022 20h30 HE
|
Allied Market Research
Portland, OR, July 03, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Ulcerative Colitis Market was estimated at $6.2 billion in 2020 and is...
AzurRx BioPharma CEO Issues Letter to Shareholders
15 avr. 2021 07h30 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., April 15, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
AzurRx BioPharma CEO Issues Letter to Shareholders
08 janv. 2021 09h00 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma Announces $8.0 Million Offerings
04 janv. 2021 07h00 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of non-systemic,...
Innovation Pharmaceuticals Announces License Agreement with Alfasigma S.p.A. for the Development and Commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative Proctosigmoiditis
22 juil. 2019 09h30 HE
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., July 22, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has...
Lyfebulb and UnitedHealth Group Announce Winners of the 2018 Innovation Challenge for Patient Entrepreneurs
26 juil. 2018 09h00 HE
|
Lyfebulb
MINNETONKA, Minn. and NEW YORK, July 26, 2018 (GLOBE NEWSWIRE) -- Lyfebulb LLC and UnitedHealth Group (NYSE:UNH) have selected Jon Margalit of Complete Start as the winner of the first-ever Lyfebulb...
Lyfebulb and UnitedHealth Group Announce 11 Finalists for Their 2018 Innovation Challenge for Patient Entrepreneurs
28 juin 2018 09h00 HE
|
Lyfebulb
Challenge recognizes companies whose founders have been affected by inflammatory bowel disease Winners to receive monetary prizes for creative and effective solutions to address IBD MINNETONKA,...
Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program
07 mai 2018 21h43 HE
|
Immuron Limited
MELBOURNE, Australia, May 07, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally...